AstraZeneca buys CDK9 portfolio

Share this article:

AstraZeneca has purchased the CDK9 portfolio of Germany-based Probiodrug AG. The Halle, Germany, biotech announced the deal Thursday, but did not disclose the price tag.

The agreement means AstraZeneca will now own the lead drug and back-up compounds associated with the molecule, which has an impact on genetic transcription connected to inflammation, a condition which is associated with cancer and inflammatory diseases.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.